New from Bosnalijek - PHARYNGAL® Spray for Sore Irritated and Inflamed Throats

Bosnalijek has expanded its non-prescription pharmaceutical product range with a new product from the group of products for local treatment of throat mucosa: PHARYNGAL®. This medicinal product is available in a modern and easy to use pharmaceutical formulation or spray for oral mucosa.


It is a combination of antiseptic and local anaesthetic and has an antimicrobial and analgesic effect, intended for symptomatic treatment of sore, irritated and inflamed throats. It relieves the accompanying symptoms, primarily irritating pain, burning sensation in the throat and difficulty in swallowing.

PHARYNGAL® spray treats mucosa of the entire oral cavity, particularly places where microorganisms accumulate. It contains breath freshening menthol and is intended for adults and children over five years of age. It does not contain sugar and is therefore suitable for use by patients with diabetes mellitus. It is available at affordable prices at all pharmacies throughout the Federation of Bosnia and Herzegovina.

This medicine will soon be available in the important markets of South Eastern Europe, CIS and Russia, where Bosnalijek has been recording strong trade growth.

Through the responsible development of its product range, in line with the latest pharmacotherapeutic trends and in accordance with its mission, Bosnalijek contributes to improving the quality of life for patients.

The Bosnalijek product range currently comprises 145 products of which 137 are medicines of different pharmaceutical forms and unit doses, based on 79 different active substances, one dietary supplement, three disinfectants for medicinal use and four disinfectants for broad consumption. Bosnalijek has launched 85 per cent of its product range in the past two decades. The structure of the product range focuses on medicines of mass therapeutic application.
August 5, 2014
Previous news
Danish journalists were convinced of the top quality of Bosnalijek Cooperation Agreement Signed between Bosnalijek and Abdi Ibrahim – Bosna ... Bosnalijek breaks its own business records Record semi-annual performance of Bosnalijek in 2022 Bosnalijek Opens New Facility for Manufacturing Liquid and Semisolid Pha ... Two Bosnalijek Teams Won Valuable Prizes at Dolorex B2B Night Relay Race ... Professional Lecture for Doctors and Patients Held On the Occasion of th ... Bosnalijek signs cooperation agreement with Mylan, a global healthcare c ... Bosnalijek Appoints US Major General David L. Grange (Ret.) as the Board ... The Third Congress of Pharmacists from Montenegro held in Bečići
april 24. 2024 |
SASE |
BSNLR - Bosnalijek d.d. Sarajevo: 12,47 3,89%